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Case Report
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patient with recurrent duodenal adenocarcinoma treated with
bevacizumab plus FOLFOX6
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Abstract: Small bowel adenocarcinoma is an uncommon gastrointestinal malignancy with limited data on
effective chemotherapy in the adjuvant setting, as well as for advanced disease. We present a case report of a
patient with recurrent duodenal adenocarcinoma after resection and adjuvant chemotherapy who experienced
a complete response to bevacizumab with oxaliplatin and 5FU (FOLFOX) followed by bevacizumab/
capecitabine maintenance therapy for 2 years. The patient continues to be disease-free 8 years after his
recurrence. This case highlights the potential of vascular endothelial growth factor (VEGF) inhibitors to
enhance chemotherapeutic regimens for advanced small bowel adenocarcinoma.
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Background
Adenocarcinoma of the small bowel is relatively rare
malignancy which carries a poor prognosis. The American
Cancer Society estimated 6,960 new cases of small
intestinal cancer diagnosed in the year 2010 (1). According
to the National Cancer Data Base, adenocarcinoma
represented 36.9% of all patients with small bowel
malignancies (2). Despite recent technical advances in
imaging and endoscopy (3), delays in diagnosis is common
and the majority (58%) of patients present with advanced
Stage III or IV disease (2). Small bowel adenocarcinoma
(SBA) also has the poorest prognosis among small bowel
cancer histologies, with relative five-year observed survival
rate of 32.5%, compared to 39.9% for stromal tumors,
49.6% for lymphomas and 64.6% for carcinoids. The
median survival and 5-year disease specific survival (DSS)
rates of patients with stage IV or recurrent disease are
9 months and 4.2%, respectively. For patients with stage III
disease, median survival is 29.8 months and 5-year survival
rate is only 35.4% (4). In addition, 5-year DSS is worse for
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patients with duodenal adenocarcinoma (28.2%) compared
to those with jejunal (37.6%) or ileal (37.8%) primaries.
Poorly differentiated tumors also carry a worse prognosis
with median survival times of 11.1 months compared to
28.6 months for those with well-differentiated tumors.
Literature regarding treatment options in the adjuvant
and metastatic setting for small bowel adenocarcinoma is
limited. There is an urgent need to evaluate novel strategies
to treat these rare malignancies. We hereby report the case
of our patient with recurrent duodenal adenocarcinoma
with a disease-free survival of more than five years after
treatment with chemotherapy and an antiangiogenic agent,
bevacizumab.
Case report
An otherwise healthy 45-year-old man presented with
significant abdominal bloating and tarry stools and
was found to have a mass in the third portion of the
duodenum. Computed tomography (CT) scan revealed
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Figure 1 Significant radiologic response of the recurrent duodenal adenocarcinoma following 2 cycles of bevacizumab and FOLFOX.

concentric wall thickening of the distal duodenum and
a mildly enlarged aortocaval lymph node. A Whipple
procedure was performed and identified a tumor in the
third portion of the duodenum. Pathologic examination of
the 2.5 cm duodenal mass revealed a moderately to poorly
differentiated duodenal adenocarcinoma with focal signet
ring features. Metastatic carcinoma was found in three of
five periduodenal lymph nodes and one omental implant.
Six weeks following surgery, the patient was started
on adjuvant chemotherapy with modified FOLFOX6 for
eight doses followed by consolidative chemoradiation. Thirty
months following surgery, he developed a local recurrence.
CT imaging revealed a soft tissue mass, measuring 4.2 cm ×
2.4 cm anterior to the left renal vein and immediately
posterior to the superior mesenteric artery. His CEA
level was elevated at 16.3 and treatment was started with
FOLFOX6 and Bevacizumab with subsequent reduction
of the tumor size to 2.4 cm × 1.8 cm after three months
(Figure 1). After 12 doses of FOLFOX6, positron emission
tomography (PET) showed a residual area without increased
FDG uptake, corresponding to the tumor seen on imaging.
The patient’s chemotherapy was switched to capecitabine
and bevacizumab due to oxaliplatin-related neuropathy.
Maintenance chemotherapy was given over a duration of
two years after he achieved a complete radiologic and PET
response to therapy. The patient continues to be diseasefree 8 years since his recurrence.
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Discussion
Currently, there is no consensus as to the benefit of, and
the optimal regimen for, adjuvant therapy for patients with
small bowel adenocarcinoma. The rarity of the disease has
limited the ability to carry out prospective clinical trials
and the optimal regimen remains undefined. Retrospective
studies reported no significant survival advantage for
patients who received adjuvant chemotherapy after resection
of their primary tumors (5-7). In fact, patients who received
adjuvant radiotherapy had shorter median survival times
at 21.6 months compared to 49.9 months for those who
did not (6). However, a multivariate analysis of one of these
retrospective studies demonstrated that the use of adjuvant
chemotherapy improved disease-free survival, and in patients
considered “high risk” (lymph node ratio ≥10%), adjuvant
therapy appear to improve survival (7). Despite a lack of
clear evidence supporting its use, the National Cancer
Data Base [1985-2005] reported an increase in the use of
adjuvant chemotherapy from 8.1% in 1985 to 22.5% in
2005 (2). Chemotherapeutic regimens have included 5-FU
or capecitabine with or without a platinum compound,
such as oxaliplatin (7). Some of these retrospective data are
summarized in Table 1.
Two years after his last adjuvant chemotherapy, our
patient had a radiographic recurrence of duodenal
adenocarcinoma with a concurrent rise in his CEA. He then
displayed a complete radiographic response to systemic
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Table 1 Selected retrospective data regarding adjuvant treatment of small bowel adenocarcinoma
Author/
Publication

Patient

Number of patients

Treatment

Outcomes

Conclusions

Bakaeen
et al./Arch
Surg 2000

Curative resection of
17 (total number of
duodenal adenocarcinoma patients underwent
surgery 68)

Concurrent
chemoradiation
with 5-FU

5-year actuarial
survival rate 54%

No impact of
chemoradiation on
survival or cancer
recurrence

Overman
et al./Acta
Oncol 2010

Margin negative surgical
30 (total patients
resection of small
undergoing surgery
bowel adenocarcinoma
54)
(duodenum 67%, Jejunum
20%, Ileum 13%)

Systemic
chemotherapy with
or without radiation
[28] and radiation
only [2]

In multivariate
analysis, use of
adjuvant therapy
was associated with
improved DFS not OS.
In high risk patients
(LN ratio ≥10%)
adjuvant therapy
improved OS but not
DFS (P=0.04)

5-year OS and
DFS did not differ
between treatment
groups.
Suggest use of
adjuvant therapy
for curatively
resected small bowel
adenocarcinoma

Swartz et al./ Pancreticoduodenectomy 14
Arch Surg
for node positive duodenal
2007
adenocarcinoma

Concurrent
chemoradiation
with 5-FU-based
chemotherapy
followed by
maintainence
chemotherapy

5-year survival rate
was 44% and
median survival for
all patients was
41 months

Chemoradiation
compared to
historical controls
improves median
survival (better
local control) does
not improve overall
survival at 5 years

Kelsey et al./
Int J Radiat
Oncol Biol
Phys 2007

Concurrent
chemoradiation
with 5-FU-based
chemotherapy

5-year survival 57%
(vs. 44% with surgery
only. P=0.42, NS).
Patients with R0
resection, 5 yr survival
83% (vs. 53 % in the
no chemoradiation
arm, P=0.07)

Local failure rates
high with surgery
alone.
Favorable outcomes
in patients
undergoing complete
resection with
chemoradiation

Non random.
16= Surgery alone
16= pre or post operative
chemoradiotherapy

16
Preoperative (N=11)
Postoperative (N=5)

chemotherapy using FOLFOX6 and bevacizumab, followed
by maintenance capecitabine and bevacizumab for a period
of two years. Remarkably, he continues to be disease-free
eight years after his recurrence.
For patients with unresected or metastatic SBA,
there was a significant improvement in overall survival
with systemic therapy compared to those who received
no therapy (12 vs. 2 months; P=0.02) based on the MD
Anderson retrospective study (5). Older fluoropyrimidinebased regimens, such as 5FU, doxorubicin with mitomycin
yielded a disappointing 18% response rate and an 8-month
median survival (8). Two of the 38 evaluable patients had
complete radiologic responses. More recently, oxaliplatin
plus capecitabine produced a 50% response rate (3 complete
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responses) with a 20.4-month median survival among
31 patients with small bowel and ampullary adenocarcinomas (9).
Excluding the patients with ampullary tumors, response rate
was 61% for the 18 patients with SBA. Further support for
the use of oxaliplatin-based regimen in SBA arose from a
retrospective French multicenter study (10). FOLFOX was
associated with a 34% response rate, median progressionfree survival of 6.9 months and median OS of 17.8 months.
Thus, oxaliplatin-based chemotherapy has been suggested
as a new standard for the treatment of metastatic or
recurrent SBA (Table 2).
This is the first case report of bevacizumab used
both with first-line FOLFOX, and with maintenance
capecitabine, in a patient with SBA resulting in a complete
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Table 2 Prospective studies in metastatic small bowel adenocarcinoma
Author/
Publication
Gibson et al./
Oncologist
2005 (8)

Number of
patients

Study
Phase II,
ECOG multiinstitutional
study

Overman et al./ Phase II
JCO 2009
MDACC single
institution
study

Patient
characteristics

Chemotherapy

Outcomes:
response rates

Outcomes:
median survival

39

Locally advanced
or metastatic
SBA or ampullary
adenocarcinoma

5-FU 600 mg/m2 (days1,
8, 29, 36), doxorubicin
30 mg/m2 (days 1, 29) &
Mitomycin C 10 mg/m2
(day 1 only)

18% (n=7/39, 2
CR)

8 months

31

Advanced,
unresectable or
metastatic SBA
or ampullary
adenocarcinoma

Capecitabine 750 mg/m2
BID (Days 1-14) and
Oxaliplatin 130 mg/m2
(day 1) every 21 days

52% (3 CR) in
the 25 metastatic
patients.
61% in SBA vs.
33% in ampullary
adenocarcinoma

20.4 months

Table 3 Selected ongoing clinical trials in small bowel adenocarcinoma. Ref: www.clinicaltrials.gov
Clinicaltrials.gov

Primary outcome
Sponsor/
Anticipated
measure
Collaborators completion date

Title

Treatment

Phase

NCT01202409

Phase II Study of
Panitumumab Combined
With Capecitabine and
Oxaliplatin (CAPOX) in
Patients With KRAS Wildtype Locally Advanced or
Metastatic Adenocarcinoma
of the Small Bowel or
Ampulla of Vater

Capecitabine
750 mg/m2 bid ×
14 days, Oxaliplatin
130 mg/m2 day 1 and
Panitumumab
9 mg/kg day 1 every
21 day cycle

II

Response Rate

M.D.
Anderson
Cancer
Center/
Amgen

Nov-14

NCT00433550

A Phase II Trial of
Pharmacogenetic-Based
Dosing of Irinotecan
(I), Oxaliplatin (O), and
Capecitabine (C ) as First-Line
Therapy for Advanced Small
Bowel Adenocarcinoma

Group 1 (6/6 UGT1A1
genotype): I (d1)+O
(d1)+C (d2-15).
Group 2 (6/7): I as
group 1, Lower doses
of O and C.
Group 3 (7/7): I, O
and C at lower doses

II

Tumor response
after 12 courses
of study
treatment

North Central
Cancer
Treatment
Group/
National
Cancer
Institute (NCI)

Dec-12

NCT01208103

Phase II Study of
Bevacizumab Combined With
Capecitabine and Oxaliplatin
(CAPOX) in Patients With
Advanced Adenocarcinoma
of the Small Bowel or
Ampulla of Vater

Capecitabine
750 mg/m2 bid ×
14 days, Oxaliplatin
130 mg/m2 day 1 and
Bevacizumab
7.5 mg/kg day 1 every
21 day cycle

II

Progression free
survival

M.D.
Anderson
Cancer
Center/
Genentech

May-15

NCT00987766

Phase Ib Trial of Gemcitabine
and Oxaliplatin (GEMOX)
With Erlotinib in Patients
With Advanced Biliary Tract
Cancer. (includes Pancreatic
Cancer, Duodenal Cancer, or
Ampullary Cancer)

Erlotinib by mouth
daily 6 days
every other week,
Gemcitabine IV
every other week,
Oxaliplatin IV every
other week

I

MTD and
recommended
phase II dose
of erlotinib in
combination with
gemcitabine and
oxaliplatin

VanderbiltIngram
Cancer
Center/
National
Cancer
Institute (NCI)

Jan-16
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radiologic response and prolonged progression-free
survival 8 years after his recurrence. Vascular endothelial
growth factor A (VEGF-A) overexpression was observed
in 91% of SBA (11). Bevacizumab is an anti-VEGF
monoclonal antibody with proven efficacy in the
treatment of metastatic colorectal cancer (12). Although
the mechanism of its efficacy has not been elucidated,
results indicate that it renders cancer cells more sensitive
to cytotoxic chemotherapy (13). Malignant epithelial
cells of the gastrointestinal tract including small bowel
adenocarcinoma express VEGF mRNA strongly, in
contrast to normal epithelium, hyperplastic polyps,
and adenomas (14). A recent study of 54 patients with
small bowel adenocarcinoma confirmed this finding.
50 (91%) of these patients’ tissue displayed expression of
VEGF-A, with high levels of its expression observed in
44 (81%) patients (11). Thus, there is basic science
evidence to suggest that bevacizumab may be effective
in SBA. Clinical success with bevacizumab in SBA was
reported in 2008 by Tsang et al. (15). A 68-year-old with
advanced adenocarcinoma of the jejunum received 8 cycles
of gemcitabine and bevacizumab with regression of disease
as measured by PET one year after presentation.
In treating this patient’s recurrence, we hypothesized
that bevacizumab would give added efficacy to the
standard cytotoxic chemotherapy regimen. As noted above,
MDACC’s prospective study’s success with capecitabine
and oxaliplatin for advanced adenocarcinoma of the small
bowel included 10% of patients who achieved a complete
radiographic response. Because the chemotherapeutic
regimens used for this patient’s recurrence also included
FOLFOX (which includes oxaliplatin) and, later,
capecitabine, it is difficult to ascertain the contribution
of bevacizumab to his excellent response. Nonetheless,
we present these findings to propose that bevacizumab
does warrant further study for treatment of SBA. Table 3
lists current studies for patients with SBA, including one
study from MD Anderson utilizing bevacizumab with
chemotherapy.
Conclusions
This is an unusual case of a patient with prolonged
disease-free survival of a recurrent small bowel signet
ring adenocarcinoma who experienced a complete
radiologic response to bevacizumab with oxaliplatin-based
chemotherapy. Further investigation of this regimen is
warranted.
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